North America Carbapenem-Based Antibiotics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Meropenem, Doripenem, Imipenem, Tebipenem, and Others), Indication (Bacterial Meningitis, Acute Pelvic Infections, Respiratory Tract Infections, Intra-Abdominal Infections, Urinary Tract Infections, and Others), and Distribution Channel (Retail Pharmacies, Online Pharmacies, and Hospital Pharmacies)
The North America carbapenem-based antibiotics market is expected to reach US$ 1,713.21 million by 2028 from US$ 1,244.59 million in 2021; it is estimated to grow at a CAGR of 4.7% from 2021-2028.
The market's growth is attributed to driving factors such as rising prevalence of bacterial infections and increasing development of generic drugs. However, the tedious and expensive process of the development of antibiotics is expected to restrain the market's growth during the forecast period.
Gram-negative bacterial infections, such as urinary tract infection (UTI), pneumonia, bloodstream infections, wound or surgical site infections, and meningitis, are commonly acquired by patients during their hospital stays. These infections are generally known as hospital-acquired infections (HAI). Infections such as UTIs and pneumonia are common in patients admitted to intensive care units. According to the US National Healthcare Safety Network, 30% of HAIs are caused by gram-negative bacteria, ~45% are due to UTIs, and ~47% are by ventilator-associated pneumonia (VAP). The prevalence of infectious diseases caused by gram-negative bacteria is rapidly increasing.
In addition, gram-negative bacterial infections are resistant to multiple drugs and have developed better resistance to available antibiotics. Antimicrobial resistance (AMR) has become a global threat to modern medicine. Therefore, constant monitoring of emerging trends is required for the clinical isolates. A group of researchers in Latvia, Europe, has studied the progression of AMR for different gram-negative bacteria. As per the research article published by them in the MDPI journal in June 2021, carbapenem-based antibiotics such as Meropenem and Ertapenem were the most effective against gram-negative bacteria, showing 3% and 5.4% resistance rates, respectively. These antibiotics are globally accepted as a treatment for gram-negative bacteria. Therefore, it is estimated that the high demand for carbapenem-based antibiotics is likely to continue in the coming years.
According to the Centers for Disease Control and Prevention (CDC), the COVID-19 pandemic led to the rise in HAI cases in 2020. Hospital admissions have grown globally, which has increased the risk of VAP as a secondary infection for COVID-19 patients. This has resulted in fueled demand for carbapenem-based antibiotics, which is aiding the market significantly.
North America Carbapenem-Based Antibiotics Market Revenue and Forecast to 2028 (US$ million)
Get more information on this report :
NORTH AMERICA CARBAPENEM-BASED ANTIBIOTICS MARKET SEGMENTATION
By Type
- Meropenem
- Imipenem
- Doripenem
- Tebipenem
- Others
By Indication
- Bacterial Meningitis
- Acute Pelvic Infections
- Respiratory Tract Infections
- Intra-Abdominal Infections
- Urinary Tract Infections
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Country
- US
- Canada
- Mexico
Company Profiles
- ACS Dobfar S.p.A
- Iterum Therapeutics plc
- DAEWOONG PHARMACEUTICAL CO., LTD
- Aurobindo Pharma Ltd
- Gland Pharma Limited
- Merck & Co., Inc.
- Sumitomo Dainippon Pharma Co., Ltd.
- Savior Lifetec
- Pfizer Inc.
- Spero Therapeutics
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Carbapenem-based Antibiotics Market – By Type
1.3.2 North America Carbapenem-based Antibiotics Market – By Indication
1.3.3 North America Carbapenem-based Antibiotics Market – By Distribution Channel
1.3.4 North America Carbapenem-based Antibiotics Market – By Country
2. Carbapenem-based Antibiotics Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Global Carbapenem-based Antibiotics Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America– PEST Analysis
4.3 Expert Opinions
5. Carbapenem-based Antibiotics Market – Key Market Dynamics
5.1 Drivers
5.1.1 Rising Prevalence of Gram-Negative Bacterial Infections
5.1.2 Increasing Production of Generic Drugs
5.2 Market Restraints
5.2.1 Tedious and Expensive Process of Antibiotic Development
5.3 Market Opportunities
5.3.1 Private and Public Partnerships
5.4 Future Trends
5.4.1 Strategic Advancement for New Antibiotic Identification
5.5 Impact Analysis
6. Carbapenem-based Antibiotics Market –Regional Analysis
6.1 North America Carbapenem-based Antibiotics Market Revenue Forecast and Analysis
7. Carbapenem-based Antibiotics Market Analysis – By Type
7.1 Overview
7.2 Carbapenem-based Antibiotics Market Revenue Share, by Type (2021 and 2028)
7.3 Meropenem
7.3.1 Overview
7.3.2 Meropenem: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Doripenem
7.4.1 Overview
7.4.2 Doripenem: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Imipenem
7.5.1 Overview
7.5.2 Imipenem: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Tebipenem
7.6.1 Overview
7.6.2 Tebipenem: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
8. Carbapenem-based Antibiotics Market – By Indication
8.1 Overview
8.2 Carbapenem-based Antibiotics Market, by Indication, 2021 and 2028 (%)
8.3 Bacterial Meningitis
8.3.1 Overview
8.3.2 Bacterial Meningitis: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Acute Pelvic Infections
8.4.1 Overview
8.4.2 Acute Pelvic Infections: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Respiratory Tract Infections
8.5.1 Overview
8.5.2 Respiratory Tract Infections: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Intra-abdominal Infections
8.6.1 Overview
8.6.2 Intra-abdominal Infections: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
8.7 Urinary Tract Infections
8.7.1 Overview
8.7.2 Urinary Tract Infections: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
9. Carbapenem-based Antibiotics Market – By Distribution Channel
9.1 Overview
9.2 Carbapenem-based Antibiotics Market, by Distribution Channel, 2021 and 2028 (%)
9.3 Retail Pharmacies
9.3.1 Overview
9.3.2 Retail Pharmacies: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Online Pharmacies
9.4.1 Overview
9.4.2 Online Pharmacies: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
9.5 Hospital Pharmacies
9.5.1 Overview
9.5.2 Hospital Pharmacies: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
10. North America Carbapenem-based Antibiotics Market –Country Analysis
10.1 North America: Carbapenem-based Antibiotics Market
10.1.1 Overview
10.1.2 North America: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ ‘Million)
10.1.3 North America: Carbapenem-based Antibiotics Market, by Type, 2019–2028 (US$ ‘Million)
10.1.4 North America: Carbapenem-based Antibiotics Market, by Indication, 2019–2028 (US$ Million)
10.1.5 North America: Carbapenem-based Antibiotics Market, by Distribution Channel, 2019–2028 (US$ Million)
10.1.6 North America: Carbapenem-based Antibiotics Market, by Country, 2021 & 2028 (%)
10.1.6.1 US: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ ‘Million)
10.1.6.1.1 US: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ ‘Million)
10.1.6.1.2 US: Carbapenem-based Antibiotics Market, by Type, 2019–2028 (US$ ‘Million)
10.1.6.1.3 US: Carbapenem-based Antibiotics Market, by Indication, 2019–2028 (US$ ‘Million)
10.1.6.1.4 US: Carbapenem-based Antibiotics Market, by Distribution Channel, 2019–2028 (US$ ‘Million)
10.1.6.2 Canada: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ ‘Million)
10.1.6.2.1 Canada: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ ‘Million)
10.1.6.2.2 Canada: Carbapenem-based Antibiotics Market, by Type, 2019–2028 (US$ ‘Million)
10.1.6.2.3 Canada: Carbapenem-based Antibiotics Market, by Indication, 2019–2028 (US$ ‘Million)
10.1.6.2.4 Canada: Carbapenem-based Antibiotics Market, by Distribution Channel, 2019–2028 (US$ ‘Million)
10.1.6.3 Mexico: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ ‘Million)
10.1.6.3.1 Mexico: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ ‘Million)
10.1.6.3.2 Mexico: Carbapenem-based Antibiotics Market, by Type, 2019–2028 (US$ ‘Million)
10.1.6.3.3 Mexico: Carbapenem-based Antibiotics Market, by Indication, 2019–2028 (US$ ‘Million)
10.1.6.3.4 Mexico: Carbapenem-based Antibiotics Market, by Distribution Channel, 2019–2028 (US$ ‘Million)
11. Impact of COVID-19 Pandemic on North America Carbapenem-based Antibiotics Market
11.1 North America: Impact Assessment of COVID-19 Pandemic
12. Carbapenem-based Antibiotics Market–Industry Landscape
12.1 Overview
12.2 Organic Developments
12.2.1 Overview
12.3 Inorganic Developments
12.3.1 Overview
13. COMPANY PROFILES
13.1 ACS Dobfar S.p.A
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Iterum Therapeutics plc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 DAEWOONG PHARMACEUTICAL CO.,LTD
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Aurobindo Pharma Ltd
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Gland Pharma Limited
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Merck & Co., Inc.
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Sumitomo Dainippon Pharma Co., Ltd.
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Savior Lifetec
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Pfizer Inc.
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Spero Therapeutics
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. North America: Carbapenem-based Antibiotics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 2. North America: Carbapenem-based Antibiotics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 3. North America: Carbapenem-based Antibiotics Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 4. US: Carbapenem-based Antibiotics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 5. US: Carbapenem-based Antibiotics Market, by Indication – Revenue and Forecast to 2028 (US$ ‘Million)
Table 6. US: Carbapenem-based Antibiotics Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ ‘Million)
Table 7. Canada: Carbapenem-based Antibiotics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 8. Canada: Carbapenem-based Antibiotics Market, by Indication – Revenue and Forecast to 2028 (US$ ‘Million)
Table 9. Canada: Carbapenem-based Antibiotics Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ ‘Million)
Table 10. Mexico: Carbapenem-based Antibiotics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 11. Mexico: Carbapenem-based Antibiotics Market, by Indication – Revenue and Forecast to 2028 (US$ ‘Million)
Table 12. Mexico: Carbapenem-based Antibiotics Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ ‘Million)
Table 13. Organic Developments in the Carbapenem-based Antibiotics Market
Table 14. Inorganic Developments in the Carbapenem-based Antibiotics Market
Table 15. Glossary of Terms, Carbapenem-based Antibiotics Market
LIST OF FIGURES
Figure 1. Carbapenem-based Antibiotics Market Segmentation
Figure 2. Carbapenem-based Antibiotics Segmentation, By Country
Figure 3. North America Carbapenem-based Antibiotics Market Overview
Figure 4. The Others Segment Held Largest Share of Type Segment in Carbapenem-based Antibiotics Market
Figure 5. North America Carbapenem-based Antibiotics Market- Leading Country Markets (US$ Million)
Figure 6. North America PEST Analysis
Figure 7. Carbapenem-based Antibiotics Market Impact Analysis of Driver and Restraints
Figure 8. North America Carbapenem-based Antibiotics Market – Revenue Forecast and Analysis – 2021- 2028
Figure 9. Carbapenem-based Antibiotics Market Revenue Share, by Type (2021 and 2028)
Figure 10. Meropenem: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 11. Doripenem: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. Imipenem: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. Tebipenem: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. Others: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. Carbapenem-based Antibiotics Market, by Indication, 2021 and 2028 (%)
Figure 16. Bacterial Meningitis: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. Acute Pelvic Infections: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. Respiratory Tract Infections: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 19. Intra-abdominal Infections: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. Urinary Tract Infections: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. Others: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. Carbapenem-based Antibiotics Market, by Distribution Channel, 2021 and 2028 (%)
Figure 23. Retail Pharmacies: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 24. Online Pharmacies: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. Hospital Pharmacies: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. North America: Carbapenem-based Antibiotics Market, by Key Country – Revenue (2021) (US$ ‘Million)
Figure 27. North America: Carbapenem-based Antibiotics Market Revenue and Forecast to 2028 (US$ ‘Million)
Figure 28. North America: Carbapenem-based Antibiotics Market, by Country, 2021 & 2028 (%)
Figure 29. US: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ ‘Million)
Figure 30. Canada: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ ‘Million)
Figure 31. Mexico: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ ‘Million)
Figure 32. Impact Of COVID-19 Pandemic in North American Country Markets
- ACS Dobfar S.p.A
- Iterum Therapeutics plc
- DAEWOONG PHARMACEUTICAL CO., LTD
- Aurobindo Pharma Ltd
- Gland Pharma Limited
- Merck & Co., Inc.
- Sumitomo Dainippon Pharma Co., Ltd.
- Savior Lifetec
- Pfizer Inc.
- Spero Therapeutics
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America carbapenem-based antibiotics market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the North America carbapenem-based antibiotics market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.